生命科学仪器2024，Vol.22Issue(4)：20-22,3.DOI:10.11967/2024220807
达格列净对急诊PCI治疗急性心梗患者心脏超声指标的影响
Effect of Dagliflozin on Cardiac Ultrasound Index in Patients with Acute Myocardial Infarction
摘要
Abstract
Objective:To explore and analyze the effect of dapagliflozin on cardiac ultrasound indicators in patients undergoing emergency percutaneous coronary intervention(PCI)for acute myocardial infarction(AMI).Method:95 patients with acute myocardial infarction(AMI)who underwent emergency PCI treatment in the hospital were se-lected as the research subjects.The treatment period was from January 2022 to October 2023.The numbers 1-95 were generated using computer random number software,and the control group(n=47)received routine symp-tomatic treatment;The observation group(n=48)consisted of individuals with odd numbers,who received addi-tional treatment with dapagliflozin after surgery.Compare the occurrence of major cardiovascular events,adverse reactions,and cardiac ultrasound indicators.After:3 months of treatment,both groups showed a decrease in end di-astolic diameter and left ventricular end diastolic volume,as well as an increase in left ventricular ejection fraction,with lower and higher values observed in the observation group(P<0.05).The incidence of major cardiovascular events in the observation group was lower than that in the control group,P<0.05.The incidence of adverse reac-tions between the two groups was compared,P>0.05.Conclusion:The application of dapagliflozin in AMI emer-gency PCI treatment patients can further improve their cardiac ultrasound indicators,reduce the occurrence of ma-jor cardiovascular events,and does not increase their medication risk.关键词
达格列净/急诊/经皮冠状动脉介入术/急性心梗/心脏超声指标Key words
Dapagliflozin/emergency treatment/Percutaneous coronary intervention/Acute myocardial infarction/Cardiac ultrasound indicators分类
医药卫生引用本文复制引用
陆稼,席银娟..达格列净对急诊PCI治疗急性心梗患者心脏超声指标的影响[J].生命科学仪器,2024,22(4):20-22,3.基金项目
酒泉市科技计划项目(沙库巴曲缬沙坦联合达格列净治疗扩张型心肌病心衰患者短中期疗效观察)(项目编号:2022MB1018) （沙库巴曲缬沙坦联合达格列净治疗扩张型心肌病心衰患者短中期疗效观察）
